Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion

Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion

Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.

Comment

CNBC

News Source

About the Author

CNBC is the world leader in business news and real-time financial market coverage. Find fast, actionable information.

Suggested Writers